Business Wire12.15.17
Regenerative medicine company Orthocell Limited is pleased to announce it has been granted a key European Patent. The patent is entitled ‘Culture medium, culturing method and use of tenocytes’ protecting the method of manufacturing tendon regeneration cells (Tenocytes) to form the Autologous Tenocyte Implantation (Ortho-ATI) product. The patent expires in 2027 and provides additional important intellectual property (IP) to protect Orthocell’s tendon repair applications, now granted in EU, USA, China, Australia, Singapore, Hong Kong, and New Zealand.
“Securing this patent for tendon repair in Europe is another milestone in strengthening our IP position as we drive our novel world leading tendon repair product into the global market. Orthocell is focused on building and maintaining patent protection for our regenerative medicine technologies and treatment processes,” Orthocell managing director Paul Anderson said.
Global IP protection for Ortho-ATI further underpins the international rollout of Orthocell’s world leading tendon repair technology. Orthocell is well positioned to commercialise Ortho-ATI with mature manufacturing facilities in place, proven safety and efficacy, published clinical data and a clear pathway to market.
Orthocell maintains an active program of patenting, with ownership of 29 granted patents across the Ortho-ATI, Ortho-ACI, and CelGro technologies, and related methods of treatment and manufacturing.
“Securing this patent for tendon repair in Europe is another milestone in strengthening our IP position as we drive our novel world leading tendon repair product into the global market. Orthocell is focused on building and maintaining patent protection for our regenerative medicine technologies and treatment processes,” Orthocell managing director Paul Anderson said.
Global IP protection for Ortho-ATI further underpins the international rollout of Orthocell’s world leading tendon repair technology. Orthocell is well positioned to commercialise Ortho-ATI with mature manufacturing facilities in place, proven safety and efficacy, published clinical data and a clear pathway to market.
Orthocell maintains an active program of patenting, with ownership of 29 granted patents across the Ortho-ATI, Ortho-ACI, and CelGro technologies, and related methods of treatment and manufacturing.